secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2023-02-14T23:59:59+00:00
Accession:  0001193125-23-036285
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan licenses U.S. rights to B7H4 x 4-1BB bispecific CLN-418 from Harbour; cash runway into 2026
--------------------------------------------------------------------------------

- Upfront $25M; up to $148M dev/reg milestones + $415M sales milestones plus tiered royalties up to high teens.
- CLN-418/HBM7008 is a clinical-stage (Phase 1) B7H4 x 4-1BB bispecific immune activator for solid tumors.
- Cash and investments $550M at end 2022; after $25M upfront would be $525M; expects cash to last into 2026.
- Company expects to have six clinical-stage assets in pipeline by end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312523036285/0001193125-23-036285-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312523036285/d436936d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-036285

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer